Correction
Accepted on 22 Nov 2024
Corrigendum: Physical Disability and Psychedelic Therapies: An Agenda for Inclusive Research and Practice
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1523364
Type at least 3 characters
533 articles
Articles
Systematic Review
Accepted on 19 Nov 2024
Phytochemicals in the Treatment of Patients with Depression: A Systemic Review
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1509109
Case Report
Accepted on 15 Nov 2024
Pregabalin treatment in a 30-year-old patient with Bainbridge-Ropers syndrome: a case-report
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1502773
- 283 views
Opinion
Published on 12 Nov 2024
Metformin in the management of antipsychotic-induced weight gain – why the ‘weight’?
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1491417
- 1,180 views
Editorial
Published on 12 Nov 2024
Editorial: Women in psychiatry 2023: psychopharmacology
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1488260
- 244 views
Systematic Review
Accepted on 07 Nov 2024
Prevalence and Solving Strategies of Drug-Related Problems in Adult Psychiatric Inpatients -A Systematic Review
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1460098
Case Report
Published on 07 Nov 2024
Vortioxetine as an alternative treatment for somatic symptom disorder: case report
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1496072
- 991 views
Opinion
Published on 06 Nov 2024
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1485337
- 1,191 views
Original Research
Accepted on 01 Nov 2024
Exposure & response prevention versus risperidone for the treatment of tic disorders: a randomized controlled trial
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1360895
- 105 views
Original Research
Published on 01 Nov 2024
Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA Adverse Event Reporting System, 2017–2023
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1442490
- 755 views
Original Research
Accepted on 29 Oct 2024
Association between polypharmacy and the long-term prescription of hypnotics in Japan: A retrospective cross-sectional study
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1471457
Editorial
Published on 22 Oct 2024
Editorial: Biological and non-pharmacological treatments of obsessive-compulsive disorder and related disorders
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1494444
- 593 views
Original Research
Published on 14 Oct 2024
Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and in vitro receptor-binding affinities
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1479625
- 705 views
Original Research
Published on 04 Oct 2024
Passiflora incarnata L., herba, in benzodiazepine tapering: long-term safety and efficacy in a real-world setting
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1471083
- 741 views
Review
Published on 04 Oct 2024
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1421554
- 1,945 views
Review
Published on 25 Sep 2024
Exploring cariprazine as a treatment option for varied depression symptom clusters
in Psychopharmacology
Frontiers in Psychiatry
doi 10.3389/fpsyt.2024.1442699
- 1,283 views